<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-06-08T03:24:32Z</responseDate><request verb="GetRecord" identifier="oai:docta.ucm.es:20.500.14352/124078" metadataPrefix="rdf">https://docta.ucm.es/rest/oai/request</request><GetRecord><record><header><identifier>oai:docta.ucm.es:20.500.14352/124078</identifier><datestamp>2025-09-18T00:03:21Z</datestamp><setSpec>com_20.500.14352_14</setSpec><setSpec>col_20.500.14352_15</setSpec></header><metadata><rdf:RDF xmlns:rdf="http://www.openarchives.org/OAI/2.0/rdf/" xmlns:ow="http://www.ontoweb.org/ontology/1#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:ds="http://dspace.org/ds/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">
   <ow:Publication rdf:about="oai:docta.ucm.es:20.500.14352/124078">
      <dc:title>Hydrocortisone Aceponate for Chronic Otitis: Long‐Term Efficacy</dc:title>
      <dc:creator>Lorente Méndez, María del Carmen</dc:creator>
      <dc:creator>Alonso Miguel, Daniel</dc:creator>
      <dc:description>Author Contributions: 
C. Lorente-Méndez: conceptualisation, methodology, acquisition andinterpretation of data and writing. D. Alonso-Miguel: acquisition,analysis and interpretation of data and writing.</dc:description>
      <dc:description>Background: 
Effective management of otitis externa (OE) requires addressing all contributing factors to prevent chronicityand recurrence. Evidence on the long-term efficacy of topical corticosteroids in preventing recurrence and secondary infectionsremains limited.Objectives: This retrospective noncontrolled study evaluated the efficacy of hydrocortisone aceponate (HCA) in resolving non-infectious chronic or recurrent (CR)- OE with or without proliferative changes, and preventing recurrence of acute episodes andsecondary infections.Animals: A total of 63 owned dogs (115 ears) with unilateral or bilateral non-infectious CR- OE were included. Most ears wereenrolled after resolving infectious otitis, as persistent inflammation or recurrence required further management.Materials and Methods: Clinical records from two dermatology referral centres (February 2022–July 2023) were reviewed.Dogs were included if they had recurrent otitis for over a year (≥ 1 year) or chronic otitis (≥ 1 month). Otitis severity was assessedusing the Otitis Index Score (OTIS3) scale, and by grading stenosis and hyperplasia severity. Enrolled patients received HCA0.584 mg/mL at weight-adjusted doses. A reactive phase continued until OTIS3 &lt; 2, followed by a proactive phase with regimensadapted to otitis severity. Concurrent treatments were recorded.Results: Recurrence was not observed in 79.1% of ears (mean follow-up 202.6 days). Among 24 relapsed ears, 29.17% recurredafter treatment discontinuation. Higher recurrence was associated with stopping therapy (p &lt; 0.001) and recent bacterial otitis(p = 0.015). No adverse effects were noted.Conclusions and Clinical Relevance: The use of HCA appears to be an effective and safe option for reactive and proactivemanagement of non-infectious CRC- OE, reducing recurrences and improving patient and owner quality-of-life


Background: 
Effective management of otitis externa (OE) requires addressing all contributing factors to prevent chronicityand recurrence. Evidence on the long-term efficacy of topical corticosteroids in preventing recurrence and secondary infectionsremains limited.
Objectives:
This retrospective noncontrolled study evaluated the efficacy of hydrocortisone aceponate (HCA) in resolving non-infectious chronic or recurrent (CR)- OE with or without proliferative changes, and preventing recurrence of acute episodes andsecondary infections.
Animals: 
A total of 63 owned dogs (115 ears) with unilateral or bilateral non-infectious CR- OE were included. Most ears wereenrolled after resolving infectious otitis, as persistent inflammation or recurrence required further management.
Materials and Methods: 
Clinical records from two dermatology referral centres (February 2022–July 2023) were reviewed.Dogs were included if they had recurrent otitis for over a year (≥ 1 year) or chronic otitis (≥ 1 month). Otitis severity was assessedusing the Otitis Index Score (OTIS3) scale, and by grading stenosis and hyperplasia severity. Enrolled patients received HCA0.584 mg/mL at weight-adjusted doses. A reactive phase continued until OTIS3 &lt; 2, followed by a proactive phase with regimensadapted to otitis severity. Concurrent treatments were recorded.
Results:
Recurrence was not observed in 79.1% of ears (mean follow-up 202.6 days). Among 24 relapsed ears, 29.17% recurredafter treatment discontinuation. Higher recurrence was associated with stopping therapy (p &lt; 0.001) and recent bacterial otitis(p = 0.015). No adverse effects were noted.
Conclusions and Clinical Relevance: 
The use of HCA appears to be an effective and safe option for reactive and proactivemanagement of non-infectious CRC- OE, reducing recurrences and improving patient and owner quality-of-life</dc:description>
      <dc:date>2025-09-17T15:04:46Z</dc:date>
      <dc:date>2025-09-17T15:04:46Z</dc:date>
      <dc:date>2025</dc:date>
      <dc:type>journal article</dc:type>
      <dc:identifier>Lorente-Méndez, C., &amp; Alonso-Miguel, D. (2025). Hydrocortisone Aceponate for Chronic Otitis: Long-Term Efficacy. Veterinary dermatology, 10.1111/vde.70008. Advance online publication. https://doi.org/10.1111/vde.70008</dc:identifier>
      <dc:identifier>0959-4493</dc:identifier>
      <dc:identifier>10.1111/vde.70008</dc:identifier>
      <dc:identifier>https://hdl.handle.net/20.500.14352/124078</dc:identifier>
      <dc:identifier>1365-3164</dc:identifier>
      <dc:identifier>https://doi.org/10.1111/vde.70008</dc:identifier>
      <dc:identifier>40757500</dc:identifier>
      <dc:language>eng</dc:language>
      <dc:rights>http://creativecommons.org/licenses/by-nc-nd/4.0/</dc:rights>
      <dc:rights>open access</dc:rights>
      <dc:rights>Attribution-NonCommercial-NoDerivatives 4.0 International</dc:rights>
      <dc:publisher>Wiley</dc:publisher>
   </ow:Publication>
</rdf:RDF></metadata></record></GetRecord></OAI-PMH>